Joe Biden heads to Theranos; Synergetics re-ups with Stryker;

@FierceMedDev: ICYMI yesterday: Bard hit with FDA warning letter affecting its vena cava filters. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Stroke-fighting Watchman, SpyGlass endoscope fuel strong Q2 for Boston Sci. Article | Follow @VarunSaxena2

@EmilyWFierce: Spotlight-savvy Kim Kardashian adds Duchesnay med to her talking points. More from FiercePharmaMarketing | Follow @EmilyWFierce

> Omnipresent, self-styled Dx revolutionary Theranos hosted Vice President Joe Biden. The company has packed its board with former U.S. government officials, as it aims to upend the diagnostics space with much cheaper blood tests that require only a finger-stick. More

> In a bit of extreme marketing, Smith & Nephew ($SNN) will have a live broadcast of a surgery on July 27 using its Journey Uni Knee System being installed via the Navio Surgical System from its partner Blue Belt Technologies. More

> Synergetics ($SURG) has re-upped with supplier Stryker ($SYK) on its 2010 deal through March 2019 for disposable aspirator instrument tips and other consumable products used with Stryker's ultrasonic aspirator console and hand pieces. More

Biotech News

@FierceBiotech: Biogen targets new biotech deals after reporting sour numbers, R&D setbacks. More | Follow @FierceBiotech

@JohnCFierce: These days, when the FDA locks the door to a cancer drug, it's saying something -- $SNSS. Release | Follow @JohnCFierce

> Denali names Carole Ho its R&D head. Chutes & Ladders

> Neos pulls off a $72M IPO to push its ADHD drugs forward. Item

> Roche backs out of its $1B cancer deal with Molecular Partners. Report

Pharma News

@FiercePharma: India's drug and CRO manufacturing travails gather pace as New Delhi calls on diplomats to help. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Two Sandoz plants in Germany and 1 in India to be shuttered by Novartis next year. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Forecast-beating Valeant ups 2015 guidance with fast-growing Xifaxan in mind. Story | Follow @CarlyHFierce

> Biogen gets beaten up as slowing Tecfidera sales lead it to trim forecast. More

> Shire CEO: We're prepared to wait for the right deal. Story

Suggested Articles

The two companies also plan to identify new potential targets and therapeutic candidates for inflammatory bowel disease, or IBD.

This would allow centralized, lab-based diagnostic hardware to process blood samples at scale, screening patients for previous infections.

GlaxoSmithKline and AstraZeneca are considering forming a joint lab to help the U.K. expand its supplies for COVID-19 testing, according to Bloomberg.